Zydus receives final approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day (USRLD: Ortho Evra Transdermal System, 150 mcg/35 mcg per day).

Norelgestromin and Ethinyl Estradiol Transdermal System contains combination hormone medication and is used to prevent pregnancy. This is the third hormonal transdermal patch to be approved from Zydus' generics portfolio. The transdermal patch will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad.

Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day had annual sales of USD 330 mn in the United States (IQVIA MAT July 2023).

The group now has 380 approvals and has so far filed over 444* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 639.70 as compared to the previous close of Rs. 643.15. The total number of shares traded during the day was 44864 in over 936 trades.

The stock hit an intraday high of Rs. 649.40 and intraday low of 637.35. The net turnover during the day was Rs. 28830426.00.

(*as of 30 th June 2023)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 FinalApproval USFDA